Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Small Cell Lung Cancer
Exiqon Diagnostics Announces KRAS Mutation Analysis for Predicting Therapeutic Response in Colorectal and Non-Small Cell Lung Cancer Patients
June 23rd, 2009
Exiqon Diagnostics announced that it now offers KRAS Mutation Analysis through its CLIA laboratory in California. Cancer treating physicians now have access to this critical test for their advanced stage colorectal and non-small cell lung cancer patients who are candidates for anti-EGFR therapy. In the United States, there are approximately 150,000 new colorectal cancer cases and over 200,000 lung cancer cases diagnosed each year.1 Many of these patients may present with advanced disease. In those cases, confirmed KRAS mutation status is important information for physicians to have when deciding on a treatment regimen that may contain EGFR-targeted therapies. Published clinical studies...
Source: Cancer Weekly (2009-06-23)
|
